FEATURES OF KIDNEY INJURY IN PATIENTS WITH COMORBIDITIES DURING CORONAVIRUS PANDEMIC
https://doi.org/10.1234/10.34822/2304-9448-2022-3-8-13
Abstract
The study aims to evaluate characteristics of kidney injury in COVID-19 patients with comorbidities. Materials and methods. Literature on the topic of pathogenesis, course, outcome, and prognosis of COVID-19 as well as randomized controlled clinical trials were reviewed. Results. COVID-19 is a severe disease that can worsen or cause kidney injury de novo. Kidney is the primary target organ for novel infection. Patients with comorbidities are also at higher risk for adverse COVID-19 outcomes.
About the Authors
E. A. Sundukova
Surgut State University, Surgut;
Maloyaroslavets Central Hospital
Russian Federation
Russian Federation
Highest Category Nephrologist
E-mail: Dr.Sundukova@yandex.ru
O. L. Aryamkinа
Surgut State University, Surgut
Russian Federation
Russian Federation
Doctor of Sciences (Medicine), Professor
E-mail: arjam56@mail.ru
References
1. Болевич С. Б., Болевич С. С. Комплексный механизм развития
2. СOVID-19 // Сеченовский вестник. 2020. Т. 11, № 2. С. 50–61.
3. Wan Y., Shang J., Graham R., Baric R. S., Li F. Receptor Recognition by
4. the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus // J Virol. 2020. Vol. 94, № 7. P. e00127-20.
5. Qi F., Qiang S., Zhang S., Zhang Z. Single Cell RNA Sequencing of 13 Human Tissues Identify Cell Types and Receptors of Human Coronaviruses // Biochem Biophys Res Comm. 2020. Vol. 526, Is. 1. P. 135–140.
6. Batlle D., Soler M. J., Sparks M. A. et al. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology // J Am Soc Nephrol. 2020. Vol. 31, Is. 7. P. 1380–1383.
7. Томилина Н. А. Covid-19: связь с патологией почек: обзор литературы // Нефрология и диализ. 2021. Т. 23, № 2. С. 147–159.
8. Wang D., Hu B., Hu C. et al. Clinical Characteristics of 138 Hospitalized
9. Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China // JAMA. 2020. Vol. 323, Is. 11. P. 1061–1069.
10. Арутюнов Г. П. и др. Международный регистр «Анализ динамики
11. Коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2» (АКТИВ SARS-CoV-2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции // Российский кардиологический журнал. 2021. Т. 26, № 4. С. 4470.
12. Столяревич Е. С. Поражение почек при COVID-19: клинические и морфологические проявления почечной патологии у 220 пациентов, умерших от COVID-19 // Нефрология и диализ. 2020. Т. 22. Спецвып. С. 46–55.
13. Зайратьянц О. В. и др. Патологическая анатомия COVID-19: опыт
14. аутопсий // Судебная медицина. 2020. Т. 6, № 4. С. 10–23.
15. Zou X., Chen K., Zoou J. et al. Single-Cell RNA-seq Data Analysis on
16. the Receptor ACE2 Expression Reveals the Potential Risk of Different Human Organs Vulnerable to 2019-nCoV Infection // Front Med. 2020. Vol. 14, Is. 2. P. 185–192.
17. Gagliardi I., Patella G., Michael A. et al. COVID-19 and the Kidney: From Epidemiology to Clinical Practice // J Clin Med. 2020. Vol. 9, Is. 8. P. 2506.
18. Cohen J. B., South A. M., Shaltout H. A., Sinclair M. R., Sparks M. A. et
19. al. Renin–Angiotensin System Blockade in the COVID-19 Pandemic // Clin Kidney J. 2021. Vol. 14, Is. Supplement_1. P. i48–i59.
20. Xiao L., Sakagami H., Miwa N. ACE2: The Key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel? // Viruses. 2020. Vol. 12, Is. 5. P. 491.
21. Li X., Geng M., Peng Y., Meng L., Lu S. Molecular Immune Pathogenesis and Diagnosis of COVID-19 // J Pharm Anal. 2020. Vol. 10, Is. 2. P. 102–108.
22. Engelmann B., Massberg S. Thrombosis as an Intravascular Effector
23. of Innate Immunity // Nat Rev Immunol. 2013. Vol. 13, Is. 1. P. 34–45.
24. Jayarangaiah A., Kariyanna P. T., Chen X., Jayarangaiah A., Kumar A. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response // Clin Appl Thromb Hemost. 2020. Vol. 26. DOI 10.1177/1076029620943293.
25. Tang N., Li D., Wang X., Sun Z. Abnormal Coagulation Parameters Are
26. Associated with Poor Prognosis in Patients with Novel Coronavirus
27. Pneumonia // J Thromb Haemost. 2020. Vol. 18, Is. 5. P. 844–847.
28. Su H., Yang M, Wan C. et al. Renal Histopathological Analysis of 26
29. Postmortem Findings of Patients with COVID-19 in China // Kidney
30. Int. 2020. Vol. 98, Is. 1. P. 219–227.
31. Hoilat G. J., Das G., Shahnawaz M., Shanley P., Bukhari S. H. COVID-19
32. Induced Collapsing Glomerulopathy and Role of APOL1 // QJM. 2020. Vol. 114, Is. 4. P. 263–264.
33. Kissling S., Rotman S., Gerber C. et al. Collapsing Glomerulopathy in
34. a COVID-19 Patient // Kidney Int. 2020. Vol. 98, Is. 1. P. 228–231.
35. Narayanan M. The Many Faces of Infection in CKD: Evolving Paradigms, Insights, and Novel Therapies // Adv Chronic Kidney Dis. 2019. Vol. 26, Is. 1. P. 5–7.
36. Cheng Y., Luo R., Wang K. et al. Kidney Disease Is Associated with In-Hospital Death of Patients with COVID-19 // Kidney Int. 2020. Vol. 97, Is. 5. P. 829–838.
37. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT)
38. Working Group. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-Analysis // JAMA. 2020. Vol. 324, Is. 13. P. 1330–1341.
39. Wu J., Li J., Zhu G. et al. Clinical Features of Maintenance Hemodialysis Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China // Clin J Am Soc Nephrol. 2020. Vol. 15, Is. 8. P. 1139–1145.
40. Nuzzo D., Picone P. Potential Neurological Effects of Severe COVID-19 Infection // Neurosci Res. 2020. Vol. 158. P. 1–5.
41. Зубкин М. Л. и др. Новая коронавирусная инфекция и гемодиализ: течение и предикторы неблагоприятного исхода // Нефрология и диализ. 2021. Т. 23, № 4. С. 489–498.
42. Edler C., Schroder A. S., Aepfelbacher M. et al. Dying with SARSCoV-
43. Infection – An Autopsy Study of the First Consecutive 80 Cases in Hamburg, Germany // International Journal of Legal Medicine. 2020. Vol. 134, Is. 4. P. 1275–1284.
44. Barron E., Bakhai C., Kar P. et al. Associations of Type 1 and Type 2
45. Diabetes with COVID-19-Related Mortality in England: A Whole-Population Study // Lancet Diabetes Endocrinol. 2020. Vol. 8, Is. 10. P. 813–822.
46. Cheng S., Zhao Y., Wang F. et al. Comorbidities’ Potential Impacts on Severe and Non-Severe Patients with COVID-19: A Systematic Review and Meta-Analysis // Medicine (Baltimore). 2021. Vol. 100, Is. 12. P. E24971.
47. Onder G. et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy // J Am Med Assoc. 2020. Vol. 323, № 18. P. 1775–1776.
48. Pati S., Mahapatra P., Kanungo S., Uddin A., Sahoo K. C. Managing
49. Multimorbidity (Multiple Chronic Diseases) Amid COVID-19 Pandemic: A Community Based Study from Odisha, India // Front Public Health. 2021. Vol. 8. P. 584408.
50. Nanda S., Toussaint L., Vincent A. et al. A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 // J Prim Care Community Health. 2021. Vol. 12. DOI 10.1177/21501327211010991.
Review
For citations:
Sundukova E.A., Aryamkinа O.L. FEATURES OF KIDNEY INJURY IN PATIENTS WITH COMORBIDITIES DURING CORONAVIRUS PANDEMIC. Vestnik SurGU. Meditsina. 2022;(3 (53)):8-13. (In Russ.) https://doi.org/10.1234/10.34822/2304-9448-2022-3-8-13
Views:
173
Email this article 
